Thyroid-related orbitopathy: a multidisciplinary perspective

References

• Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthal. Plast. Reconstr. Surg.9(2), 77–82 (1993).
   PubMed Web of Science ®Google Scholar
• Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr. Rev.24, 802–835 (2003).
   PubMed Web of Science ®Google Scholar
• Feliciello A, Porcellini A, Ciullo I, Bonavolontà G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves’ disease retro-orbital tissue. Lancet342, 337–338 (1993).
   PubMed Web of Science ®Google Scholar
• Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab.83, 998–1002 (1998).
   PubMed Web of Science ®Google Scholar
• Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J. Immunol.168, 942–950 (2002).
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J. Clin. Endocrinol. Metab.89, 5076–5080 (2004).
   PubMed Web of Science ®Google Scholar
• Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J. Immunol.170, 6348–6354 (2003).
   PubMed Web of Science ®Google Scholar
• Tsui S, Naik V, Hoa N et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J. Immunol.181(6), 4397–4405 (2008).
   PubMed Web of Science ®Google Scholar
• Ando T, Davies TF. Monoclonal antibodies to the thyrotropin receptor. Clin. Dev. Immunol.12(2), 137–143 (2005).
   PubMedGoogle Scholar
• Imai Y, Ibaraki K, Odajima R, Shishiba Y. Effects of dibutyryl cyclic AMP on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts in culture. Endocr. J.41(6), 645–654 (1994).
   PubMedGoogle Scholar
• Watson EM, Pearce RH. The mucopolysaccharide content of the skin in localized (pre-tibial) myxedema. Am. J. Clin. Pathol.17, 507 (1947).
   PubMedGoogle Scholar
• Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr. Rev.10, 366–391 (1989).
   PubMed Web of Science ®Google Scholar
• Rotella CM, Zonefrati R, Toccafondi R et al. Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves’ sera. J. Clin. Endocrinol. Metab.62, 357–367 (1986).
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J. Clin. Endocrinol. Metab.89, 5076–5080 (2004).
   PubMed Web of Science ®Google Scholar
• van Zeijl CJ, Fliers E, van Koppen CJ et al. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves’ disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves’ ophthalmopathy patients. Thyroid20(5), 535–544 (2010).
   PubMed Web of Science ®Google Scholar
• Bucala R. Circulating fibrocytes: cellular basis for NSF. J. Am. Coll. Radiol.5, 36–39 (2008).
   PubMedGoogle Scholar
• Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid12, 197–203 (2002).
   PubMed Web of Science ®Google Scholar
• Douglas RS, Afifiyan NF, Hwang CJ et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab.95(1), 430–438 (2010).
   PubMed Web of Science ®Google Scholar
• Ademoglu E, Ozbey N, Erbil Y. Determination of oxidative stress in thyroid tissue and plasma of patients with Graves’ disease. Eur. J. Intern. Med.17, 545–550 (2006).
   PubMed Web of Science ®Google Scholar
• Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell. Mol. Life Sci.63, 414–434 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai CC, Kao SC, Cheng CY et al. Oxidative stress change by systemic corticosteroids treatment of patients with active Graves’ ophthalmopathy. Arch. Ophthalmol.125, 1652–1656 (2007).
   PubMedGoogle Scholar
• Tsai CC, Cheng CY, Liu CY et al. Oxidative stress in patients with Graves’ ophthalmopathy: relationship between oxidative DNA damage and clinical evolution. Eye23(8), 1725–1730 (2009).
   PubMedGoogle Scholar
• Wei YS, Lan Y, Tang RG et al. Single nucleotide polymorphism and haplotype association of the interleukin-8 gene with nasopharyngeal carcinoma. Clin. Immunol.125(3), 309–317 (2007).
   PubMedGoogle Scholar
• Gu LQ, Jia HY, Zhao YJ et al. Association studies of interleukin-8 gene in Graves’ disease and Graves’ ophthalmopathy. Endocrine36(3), 452–456 (2009).
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. The philosophy of Graves’ ophthalmopathy. Orbit24, 165–171 (2005).
   PubMedGoogle Scholar
• Wiersinga WM, Perros P, Kahaly GJ et al.; European Group on Graves’ Orbitopathy (EUGOGO). Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur. J. Endocrinol.155(3), 387–389 (2006).
   PubMed Web of Science ®Google Scholar
• Douglas RS, Tsirbas A, Gordon M et al. International Thyroid Eye Disease Society. Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Arch. Ophthalmol.127(9), 1155–1160 (2009).
   PubMedGoogle Scholar
• Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J. Clin. Endocrinol. Metab.95(5), 2123–2131 (2010).
   PubMed Web of Science ®Google Scholar
• Dragan LR, Seiff SR, Lee DC. Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Ophthal. Plast. Reconstr. Surg.22(1), 13–19 (2006).
   PubMedGoogle Scholar
• Gorman CA, Garrity JA, Fatourechi V et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology108, 1523–1534 (2001).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson AJ et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid18(3), 333–346 (2008).
   PubMed Web of Science ®Google Scholar
• Prummel MF, Wiersinga WM, Mourits M et al. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch. Intern. Med.150, 1098–1101 (1990).
   PubMedGoogle Scholar
• Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin. Endocrinol.68, 814–820 (2008).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N. Engl. J. Med.338, 73–78 (1998).
   PubMed Web of Science ®Google Scholar
• Kung AWC, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease: prognostic factors and the role of methimazole. J. Clin. Endocrinol. Metab.79, 542–546 (1994).
   PubMed Web of Science ®Google Scholar
• El-Kaissi S, Bowden J, Henry MJ et al. Association between radioiodine therapy for Graves’ hyperthyroidism and thyroid-associated ophthalmopathy. Int. Ophthalmol.30(4), 397–405 (2010).
   PubMedGoogle Scholar
• Sisson JC, Schipper MJ, Nelson CC et al. Radioiodine therapy and Graves’ ophthalmopathy. J. Nucl. Med.49(6), 923–930 (2008).
   PubMedGoogle Scholar
• Nart A, Uslu A, Aykas A et al. Total thyroidectomy for the treatment of recurrent graves’ disease with ophthalmopathy. Asian J. Surg.31(3), 115–118 (2008).
   PubMedGoogle Scholar
• Prummel MF, Mourits M Ph, Blank L et al. Randomized double-blind trial of prednisone verus radiotherapy in Graves’ ophthalmopathy. Lancet342, 949–954 (1993).
   PubMed Web of Science ®Google Scholar
• Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin. Endocrinol.49, 21–28 (1998).
   PubMedGoogle Scholar
• Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin. Endocrinol.45, 477–481 (1996).
   PubMed Web of Science ®Google Scholar
• Glinoer D, de Nayer P, Bex M et al. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs. Eur. J. Endocrinol.144, 475–483 (2001).
   PubMed Web of Science ®Google Scholar
• Zoumalan CI, Cockerham KP, Turbin RE et al. Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J. Neuroophthalmol.27(3), 205–214 (2007).
   PubMedGoogle Scholar
• Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood83, 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Nielsen CH, El Fassi D, Hasselbalch HC et al. B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves’ ophthalmopathy the latest addition to an expanding family. Expert Opin. Biol. Ther.7, 1061–1078 (2007).
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L. The rationale for B lymphocyte depletion in Graves’ disease: monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol.154, 623–632 (2006).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol.156, 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Campi I, Bonomi M et al. Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions. Clin. Exp. Immunol.161(3), 436–443 (2010).
   PubMed Web of Science ®Google Scholar
• Khanna D, Chong KK, Afifiyan NF et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology117(1), 133–139.e2 (2010).
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Rosler HP, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J. Clin. Endocrinol. Metab.85, 102–108 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson KT, Wittig A, Loesch C, Esser J, Sauerwein W, Eckstein AK. A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves’ orbitopathy. Graefes Arch. Clin. Exp. Ophthalmol.248(1), 103–109 (2010).
   PubMedGoogle Scholar
• Bartley GB, Fatourechi V, Kadrmas EF et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am. J. Ophthalmol.121, 284–290 (1996).
   PubMed Web of Science ®Google Scholar
• Elston JS. The management of blepharospasm and hemi facial spasm. J. Neurol.239, 5–8 (1992).
   PubMedGoogle Scholar
• Lee J, Elston J, Vickers S et al. Botulinum toxin therapy for squint. Eye2, 24–28 (1998).
   Google Scholar
• Kirkness CM, Adams GG, Dilly PN, Lee JP. Botulinum toxin A-induced protective ptosis in corneal disease. Ophthalmology95, 473–480 (1998).
   Google Scholar
• Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology109(6), 1183–1187 (2002).
   PubMed Web of Science ®Google Scholar
• Costa PG, Saraiva FP, Pereira IC, Monteiro ML, Matayoshi S. Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye23(4), 767–773 (2009).
   PubMed Web of Science ®Google Scholar
• Kramar P. Management of eye changes of Graves’ disease. Surv. Ophthalmol.18, 369–378 (1974).
   Google Scholar
• Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology87, 1044–1049 (1980).
   PubMed Web of Science ®Google Scholar
• Dunn WJ, Arnold AC, O’Connor PS. Botulinum toxin for the treatment of dysthyroid ocular myopathy. Ophthalmology93, 470–475 (1986).
   PubMed Web of Science ®Google Scholar
• Kikkawa DO, Cruz RC Jr, Christian WK et al. Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: effects on intraocular pressure. Am. J. Ophthalmol.135(4), 427–431 (2003).
   PubMed Web of Science ®Google Scholar
• Korn BS, Seo SW, Levi L, Granet DB, Kikkawa DO. Optic neuropathy associated with botulinum A toxin in thyroid-related orbitopathy. Ophthal. Plast. Reconstr. Surg.23(2), 109–114 (2007).
   PubMed Web of Science ®Google Scholar
• Putterman AM, Fett DR. Mueller’s muscle in the treatment of upper eyelid retraction: a 12 year study. Ophthalmic Surg.17, 361–367 (1986).
   PubMedGoogle Scholar
• Harvey JT, Anderson RL. The aponeurotic approach to eyelid retraction. Ophthalmology88, 513–524 (1981).
   PubMed Web of Science ®Google Scholar
• Elner VM, Hassan AS, Frueh BR. Graded full-thickness anterior blepharotomy for upper eyelid retraction. Arch. Ophthalmol.122(1), 55–60 (2004).
   PubMedGoogle Scholar
• McCracken MS, del Prado JD, Granet DB, Levi L, Kikkawa DO. Combined eyelid and strabismus surgery: examining conventional surgical wisdom. J. Pediatr. Ophthalmol. Strabismus45(4), 220–224 (2008).
   PubMedGoogle Scholar
• Gomi CF, Yang SW, Granet DB et al. Change in proptosis following extraocular muscle surgery: effects of muscle recession in thyroid-associated orbitopathy. J. AAPOS11(4), 377–380 (2007).
   PubMed Web of Science ®Google Scholar
• Kikkawa DO, Pornpanich K, Cruz RC Jr, Levi L, Granet DB. Graded orbital decompression based on severity of proptosis. Ophthalmology109(7), 1219–1224 (2002).
   PubMed Web of Science ®Google Scholar
• Graham SM, Brown CL, Carter KD, Song A, Nerad JA. Medial and lateral orbital wall surgery for balanced decompression in thyroid eye disease. Laryngoscope113(7), 1206–1209 (2003).
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Perry JD, Hortaleza V, Tong JT. Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy. Ophthal. Plast. Reconstr. Surg.(16), 271–277 (2000).
   PubMedGoogle Scholar
• Trokel SL, Kazim M, Moore S. Orbital fat removal decompression for Graves’ orbitopathy. Ophthalmology100, 674–682 (1993).
   PubMed Web of Science ®Google Scholar
• Wu CH, Chang TC, Liao SL. Results and predictability of fat-removal orbital decompression for disfiguring graves exophthalmos in an Asian patient population. Am. J. Ophthalmol.145(4), 755–759 (2008).
   PubMed Web of Science ®Google Scholar
• Cho RI, Choe CH, Elner VM. Ultrasonic bone removal versus high-speed burring for lateral orbital decompression: comparison of surgical outcomes for the treatment of thyroid eye disease. Ophthal. Plast. Reconstr. Surg.26(2), 83–87 (2010).
   PubMed Web of Science ®Google Scholar
• Hu WD, Annunziata CC, Chokthaweesak W et al. Radiographic analysis of extraocular muscle volumetric changes in thyroid-related orbitopathy following orbital decompression. Ophthal. Plast. Reconstr. Surg.26(1), 1–6 (2010).
   PubMed Web of Science ®Google Scholar
• Baldeschi L, Lupetti A, Vu P et al. Reactivation of Graves’ orbitopathy after rehabilitative orbital decompression. Ophthalmology114, 1395–402 (2007).
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF et al. Long-term follow-up of Graves’ ophthalmopathy in an incident cohort. Ophthalmology103, 958–962 (1996).
   PubMed Web of Science ®Google Scholar
• Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid7, 885–889 (1997).
   PubMed Web of Science ®Google Scholar
• Terwee CB, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur. J. Endocrinol.146, 751–757 (2002).
   PubMed Web of Science ®Google Scholar
• Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM. Test–retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves’ ophthalmopathy. J. Clin. Epidemiol.52, 875–884 (1999).
   PubMed Web of Science ®Google Scholar
• Farid M, Roch-Levecq AC, Levi L, Brody BL, Granet DB, Kikkawa DO. Psychological disturbance in graves ophthalmopathy. Arch. Ophthalmol.123(4), 491–496 (2005).
   PubMedGoogle Scholar
• Lee H, Roh HS, Yoon JS, Lee SY. Assessment of quality of life and depression in Korean patients with Graves’ ophthalmopathy. Korean J. Ophthalmol.24(2), 65–72 (2010).
   PubMedGoogle Scholar
• Ponto KA, Kahaly GJ. Quality of life in patients suffering from thyroid orbitopathy. Pediatr. Endocrinol. Rev.7(Suppl. 2), 245–249 (2010).
   PubMedGoogle Scholar
• Ducharme A, Doyon O, White M, Rouleau JL, Brophy JM. Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ173(1), 40–45 (2005).
   PubMed Web of Science ®Google Scholar
• Sperl-Hillen JM, O’Connor PJ. Factors driving diabetes care improvement in a large medical group: 10 years of progress. Am. J. Manag. Care5, S177–S185 (2005).
   Google Scholar